0000000000615040

AUTHOR

Amelia Cimmino

0000-0002-0004-9299

showing 3 related works from this author

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic

2020

On March 11, 2020, the WHO has declared the coronavirus disease 2019 (COVID-19) a global pandemic. As the last few months have profoundly changed the delivery of health care in the world, we should recognize the effort of numerous comprehensive cancer centers to share experiences and knowledge to develop best practices to care for oncological patients during the COVID-19 pandemic. Patients as well as physicians must be aware of all these constraints and profound social, personal, and medical challenges posed by the tackling of this deadly disease in everyday life in order to adjust to such a completely novel scenario. This review will discuss facing the challenges and the current approaches…

0301 basic medicineCancer ResearchCoronavirus disease 2019 (COVID-19)Best practiceDiseasechemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineNursingPolitical scienceHealth carePandemicmedicinecancersevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Everyday lifebusiness.industrypandemicPerspective (graphical)Cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisPerspectivecoronavirus disease 2019 (COVID-19)businessFrontiers in Oncology
researchProduct